# Safety, Activity and Cell Kinetics of CYAD-211 in Patients With Relapsed or Refractory Multiple Myeloma

> **NCT04613557** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Celyad Oncology SA** · enrollment: 18 (actual)

## Conditions studied

- Relapse/Refractory Multiple Myeloma

## Interventions

- **BIOLOGICAL:** CYAD-211
- **DRUG:** Endoxan
- **DRUG:** Fludara

## Key facts

- **NCT ID:** NCT04613557
- **Lead sponsor:** Celyad Oncology SA
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2020-11-16
- **Primary completion:** 2022-12-21
- **Final completion:** 2037-02
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2023-08-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04613557

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04613557, "Safety, Activity and Cell Kinetics of CYAD-211 in Patients With Relapsed or Refractory Multiple Myeloma". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT04613557. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*